Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis

Advances in Enzyme Regulation

Volumn 48, Issue 1, 2008, Pages 98-112

  Johnson, Daniel E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; GENETICS; HUMAN; MYELOID PROGENITOR CELL; PATHOLOGY; PHYSIOLOGY;

CELL DIFFERENTIATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAP KINASE KINASE KINASES; MYELOID PROGENITOR CELLS; SRC-FAMILY KINASES;

EID: 51349158338     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2007.11.002     Document Type: Article

References (144)

1. Abram C.L., and Courtneidge S.A. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 254 (2000) 1-13
2. Alessi D.R., Saito Y., Campbell D.G., Cohen P., Sithanandam G., Rapp U., et al. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J 13 (1994) 1610-1619
3. Ballif B.A., and Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 12 (2001) 397-408
4. Barnekow A., and Gessler M. Activation of the pp60c-src kinase during differentiation of monomyelocytic cells in vitro. EMBO J 5 (1986) 701-705
5. Blalock W.L., Pearce M., Steelman L.S., Franklin R.A., McCarthy S.A., Cherwinski H., et al. A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. Oncogene 19 (2000) 526-536
6. Boggon T.J., and Eck M.J. Structure and regulation of Src family kinases. Oncogene 23 (2004) 7918-7927
7. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., and Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286 (1999) 1358-1362
8. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 (2001) 37-40
9. Cooper J.A., Gould K.L., Cartwright C.A., and Hunter T. Tyr527 is phosphorylated in pp60c-src: implications for regulation. Science 231 (1986) 1431-1434
10. Corey S.J., and Anderson S.M. Src-related protein tyrosine kinases in hematopoiesis. Blood 93 (1999) 1-14
11. Corey S.J., Burkhardt A.L., Bolen J.B., Geahlen R.L., Tkatch L.S., and Tweardy D.J. Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases. Proc Natl Acad Sci U S A 91 (1994) 4683-4687
12. Cortes J., Rousselot P., Kim D.W., Ritchie E., Hamerschlak N., Coutre S., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 (2007) 3207-3213
13. Cortez D., Reuther G., and Pendergast A.M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15 (1997) 2333-2342
14. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 (1994) 841-852
15. Crews C.M., Alessandrini A., and Erikson R.L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258 (1992) 478-480
16. Danhauser-Riedl S., Warmuth M., Druker B.J., Emmerich B., and Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 56 (1996) 3589-3596
17. Davidson D., Chow L.M., and Veillette A. Chk, a Csk family tyrosine protein kinase, exhibits Csk-like activity in fibroblasts, but not in an antigen-specific T-cell line. J Biol Chem 272 (1997) 1355-1362
18. Deng X., Ruvolo P., Carr B., and May Jr. W.S. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci U S A 97 (2000) 1578-1583
19. Dent P., Haser W., Haystead T.A., Vincent L.A., Roberts T.M., and Sturgill T.W. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 257 (1992) 1404-1407
20. Dong F., Brynes R.K., Tidow N., Welte K., Lowenberg B., and Touw I.P. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 333 (1995) 487-493
21. Erickson P., Gao J., Chang K.S., Look T., Whisenant E., Raimondi S., et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80 (1992) 1825-1831
22. Fitzer-Attas C.J., Lowry M., Crowley M.T., Finn A.J., Meng F., DeFranco A.L., et al. Fcgamma receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn. J Exp Med 191 (2000) 669-682
23. Gee C.E., Griffin J., Sastre L., Miller L.J., Springer T.A., Piwnica-Worms H., et al. Differentiation of myeloid cells is accompanied by increased levels of pp60c-src protein and kinase activity. Proc Natl Acad Sci U S A 83 (1986) 5131-5135
24. Gilliland D.G., and Griffin J.D. Role of FLT3 in leukemia. Curr Opin Hematol 9 (2002) 274-281
25. Glasow A., Prodromou N., Xu K., von Lindern M., and Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 105 (2005) 341-349
26. Gobert Gosse S., Bourgin C., Liu W.Q., Garbay C., and Mouchiroud G. M-CSF stimulated differentiation requires persistent MEK activity and MAPK phosphorylation independent of Grb2-Sos association and phosphatidylinositol 3-kinase activity. Cell Signal 17 (2005) 1352-1362
27. Gonfloni S., Williams J.C., Hattula K., Weijland A., Wierenga R.K., and Superti-Furga G. The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. EMBO J 16 (1997) 7261-7271
28. Graves L.M., Guy H.I., Kozlowski P., Huang M., Lazarowski E., Pope R.M., et al. Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature 403 (2000) 328-332
29. Guilhot F., Apperley J., Kim D.W., Bullorsky E.O., Baccarani M., Roboz G.J., et al. Destines induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
30. Hamaguchi I., Yamaguchi N., Suda J., Iwama A., Hirao A., Hashiyama M., et al. Analysis of CSK homologous kinase (CHK/HYL) in hematopoiesis by utilizing gene knockout mice. Biochem Biophys Res Commun 224 (1996) 172-179
31. Harder K.W., Parsons L.M., Armes J., Evans N., Kountouri N., Clark R., et al. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 15 (2001) 603-615
32. Herrera R., Hubbell S., Decker S., and Petruzzelli L. A role for the MEK/MAPK pathway in PMA-induced cell cycle arrest: modulation of megakaryocytic differentiation of K562 cells. Exp Cell Res 238 (1998) 407-414
33. Hill C.S., Marais R., John S., Wynne J., Dalton S., and Treisman R. Functional analysis of a growth factor-responsive transcription factor complex. Cell 73 (1993) 395-406
34. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
35. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822
36. Hu X., Moscinski L.C., Valkov N.I., Fisher A.B., Hill B.J., and Zuckerman K.S. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth Differ 11 (2000) 191-200
37. Hunter M.G., and Avalos B.R. Phosphatidylinositol 3′-kinase and SH2-containing inositol phosphatase (SHIP) are recruited by distinct positive and negative growth-regulatory domains in the granulocyte colony-stimulating factor receptor. J Immunol 160 (1998) 4979-4987
38. Ihle J.N., and Kerr I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 11 (1995) 69-74
39. Jin A., Kurosu T., Tsuji K., Mizuchi D., Arai A., Fujita H., et al. BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion. Oncogene 25 (2006) 4332-4340
40. de Koning J.P., Soede-Bobok A.A., Schelen A.M., Smith L., van Leeuwen D., Santini V., et al. Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor. Blood 91 (1998) 1924-1933
41. Kakizuka A., Miller Jr. W.H., Umesono K., Warrell Jr. R.P., Frankel S.R., Murty V.V., et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66 (1991) 663-674
42. Kang C.D., Yoo S.D., Hwang B.W., Kim K.W., Kim D.W., Kim C.M., et al. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk Res 24 (2000) 527-534
43. Kantarjian H.M., Giles F., Quintas-Cardama A., and Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13 (2007) 1089-1097
44. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270 (1995) 16483-16486
45. Katagiri K., Katagiri T., Koyama Y., Morikawa M., Yamamoto T., and Yoshida T. Expression of src family genes during monocytic differentiation of HL-60 cells. J Immunol 146 (1991) 701-707
46. Katagiri K., Yokoyama K.K., Yamamoto T., Omura S., Irie S., and Katagiri T. Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. J Biol Chem 271 (1996) 11557-11562
47. Kim S.C., Hahn J.S., Min Y.H., Yoo N.C., Ko Y.W., and Lee W.J. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 93 (1999) 3893-3899
48. Klejman A., Schreiner S.J., Nieborowska-Skorska M., Slupianek A., Wilson M., Smithgall T.E., et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21 (2002) 5766-5774
49. Koegl M., Zlatkine P., Ley S.C., Courtneidge S.A., and Magee A.I. Palmitoylation of multiple Src-family kinases at a homologous N-terminal motif. Biochem J 303 3 (1994) 749-753
50. Kogan S.C., Lagasse E., Atwater S., Bae S.C., Weissman I., Ito Y., et al. The PEBP2betaMYH11 fusion created by Inv(16) (p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci U S A 95 (1998) 11863-11868
51. Kornblau S.M., Womble M., Qiu Y.H., Jackson C.E., Chen W., Konopleva M., et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108 (2006) 2358-2365
52. Kyriakis J.M., App H., Zhang X.F., Banerjee P., Brautigan D.L., Rapp U.R., et al. Raf-1 activates MAP kinase-kinase. Nature 358 (1992) 417-421
53. Lazar D.F., Wiese R.J., Brady M.J., Mastick C.C., Waters S.B., Yamauchi K., et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem 270 (1995) 20801-20807
54. Ley R., Balmanno K., Hadfield K., Weston C., and Cook S.J. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278 (2003) 18811-18816
55. Link D.C., and Zutter M. The proto-oncogene c-fgr is expressed in normal mantle zone B lymphocytes and is developmentally regulated during myelomonocytic differentiation in vivo. Blood 85 (1995) 472-479
56. Lionberger J.M., Wilson M.B., and Smithgall T.E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 275 (2000) 18581-18585
57. Liu K.D., Gaffen S.L., and Goldsmith M.A. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 10 (1998) 271-278
58. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47 (2004) 6658-6661
59. Lowell C.A., Fumagalli L., and Berton G. Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions. J Cell Biol 133 (1996) 895-910
60. Lunghi P., Tabilio A., Dall'Aglio P.P., Ridolo E., Carlo-Stella C., Pelicci P.G., et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia 17 (2003) 1783-1793
61. Mansour S.J., Matten W.T., Hermann A.S., Candia J.M., Rong S., Fukasawa K., et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265 (1994) 966-970
62. Marcinkowska E., Garay E., Gocek E., Chrobak A., Wang X., and Studzinski G.P. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3. Exp Cell Res 312 (2006) 2054-2065
63. Martin G.S. Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature 227 (1970) 1021-1023
64. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46 (2006) 249-279
65. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773 (2007) 1263-1284
66. McCubrey J.A., Steelman L.S., Franklin R.A., Abrams S.L., Chappell W.H., Wong E.W., et al. Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Adv Enzyme Regul 47 (2007) 64-103
67. Meier R.W., Bielke W., Chen T., Niklaus G., Friis R.R., and Tobler A. Lyn, a src-like tyrosine-specific protein kinase, is expressed in HL60 cells induced to monocyte-like or granulocyte-like cells. Biochem Biophys Res Commun 185 (1992) 91-95
68. Melnick A., and Licht J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93 (1999) 3167-3215
69. Meng F., and Lowell C.A. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J Exp Med 185 (1997) 1661-1670
70. Mermel C.H., McLemore M.L., Liu F., Pereira S., Woloszynek J., Lowell C.A., et al. Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis. Blood 108 (2006) 2562-2568
71. Milella M., Estrov Z., Kornblau S.M., Carter B.Z., Konopleva M., Tari A., et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99 (2002) 3461-3464
72. Milella M., Konopleva M., Precupanu C.M., Tabe Y., Ricciardi M.R., Gregorj C., et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood 109 (2007) 2121-2129
73. Milella M., Kornblau S.M., Estrov Z., Carter B.Z., Lapillonne H., Harris D., et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108 (2001) 851-859
74. Miranda M.B., Dyer K.F., Grandis J.R., and Johnson D.E. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells. Leukemia 17 (2003) 390-400
75. Miranda M.B., and Johnson D.E. Signal transduction pathways that contribute to myeloid differentiation. Leukemia 21 (2007) 1363-1377
76. Miranda M.B., McGuire T.F., and Johnson D.E. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 16 (2002) 683-692
77. Miranda M.B., Xu H., Torchia J.A., and Johnson D.E. Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway. Leuk Res 29 (2005) 1293-1306
78. Miyazaki Y., Katamine S., Kohno T., Moriuchi R., Miyamoto T., and Tomonaga M. fgr proto-oncogene is expressed during terminal granulocytic differentiation of human promyelocytic HL60 cells. Exp Hematol 21 (1993) 366-371
79. Moarefi I., LaFevre-Bernt M., Sicheri F., Huse M., Lee C.H., Kuriyan J., et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385 (1997) 650-653
80. Mocsai A., Ligeti E., Lowell C.A., and Berton G. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol 162 (1999) 1120-1126
81. Mueller B.U., Pabst T., Osato M., Asou N., Johansen L.M., Minden M.D., et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100 (2002) 998-1007
82. Nada S., Okada M., MacAuley A., Cooper J.A., and Nakagawa H. Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature 351 (1991) 69-72
83. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62 (2002) 4236-4243
84. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112 (2003) 859-871
85. Nakada S., Kawano T., Saito-akita S., Iwase S., Horiguchi-Yamada J., Ohno T., et al. MEK and p38MAPK inhibitors potentiate TNF-alpha induced apoptosis in U937 cells. Anticancer Res 21 (2001) 167-171
86. Nawata R., Yujiri T., Nakamura Y., Ariyoshi K., Takahashi T., Sato Y., et al. MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation. Oncogene 22 (2003) 7774-7780
87. Notario V., Gutkind J.S., Imaizumi M., Katamine S., and Robbins K.C. Expression of the fgr protooncogene product as a function of myelomonocytic cell maturation. J Cell Biol 109 (1989) 3129-3136
88. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
89. Okamoto M., Hayakawa F., Miyata Y., Watamoto K., Emi N., Abe A., et al. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 21 (2007) 403-410
90. Pages G., Lenormand P., L'Allemain G., Chambard J.C., Meloche S., and Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 90 (1993) 8319-8323
91. Pandolfi P.P., Grignani F., Alcalay M., Mencarelli A., Biondi A., LoCoco F., et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6 (1991) 1285-1292
92. Papin C., Eychene A., Brunet A., Pages G., Pouyssegur J., Calothy G., et al. B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222. Oncogene 10 (1995) 1647-1651
93. Payne D.M., Rossomando A.J., Martino P., Erickson A.K., Her J.H., Shabanowitz J., et al. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J 10 (1991) 885-892
94. Platanias L.C. Map kinase signaling pathways and hematologic malignancies. Blood 101 (2003) 4667-4679
95. Radomska H.S., Basseres D.S., Zheng R., Zhang P., Dayaram T., Yamamoto Y., et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med 203 (2006) 371-381
96. Redner R.L. Variations on a theme: the alternate translocations in APL. Leukemia 16 (2002) 1927-1932
97. Resh M.D. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta 1451 (1999) 1-16
98. Ricciardi M.R., McQueen T., Chism D., Milella M., Estey E., Kaldjian E., et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 19 (2005) 1543-1549
99. Robinson L.J., Xue J., and Corey S.J. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 33 (2005) 469-479
100. Roginskaya V., Zuo S., Caudell E., Nambudiri G., Kraker A.J., and Corey S.J. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 13 (1999) 855-861
101. Roskoski Jr. R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331 (2005) 1-14
102. Ross S.E., Radomska H.S., Wu B., Zhang P., Winnay J.N., Bajnok L., et al. Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol 24 (2004) 675-686
103. Sachs L. Constitutive uncoupling of pathways of gene expression that control growth and differentiation in myeloid leukemia: a model for the origin and progression of malignancy. Proc Natl Acad Sci U S A 77 (1980) 6152-6156
104. Sakhinia E., Faranghpour M., Liu Yin J.A., Brady G., Hoyland J.A., and Byers R.J. Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol 130 (2005) 233-248
105. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., and Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 3 (1999) 639-648
106. Seth A., Gonzalez F.A., Gupta S., Raden D.L., and Davis R.J. Signal transduction within the nucleus by mitogen-activated protein kinase. J Biol Chem 267 (1992) 24796-24804
107. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
108. Shelly C., Petruzzelli L., and Herrera R. PMA-induced phenotypic changes in K562 cells: MAPK-dependent and -independent events. Leukemia 12 (1998) 1951-1961
109. Sherr C.J., and Rettenmier C.W. The fms gene and the CSF-1 receptor. Cancer Surv 5 (1986) 221-232
110. Sherr C.J., Roussel M.F., and Rettenmier C.W. Colony-stimulating factor-1 receptor (c-fms). J Cell Biochem 38 (1988) 179-187
111. Shonai T., Adachi M., Sakata K., Takekawa M., Endo T., Imai K., et al. MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells. Cell Death Differ 9 (2002) 963-971
112. Sicheri F., Moarefi I., and Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385 (1997) 602-609
113. Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program (2006) 178-184
114. Smart J.E., Oppermann H., Czernilofsky A.P., Purchio A.F., Erikson R.L., and Bishop J.M. Characterization of sites for tyrosine phosphorylation in the transforming protein of Rous sarcoma virus (pp60v-src) and its normal cellular homologue (pp60c-src). Proc Natl Acad Sci U S A 78 (1981) 6013-6017
115. Snaddon J., Smith M.L., Neat M., Cambal-Parrales M., Dixon-McIver A., Arch R., et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 37 (2003) 72-78
116. Songyang Z., Shoelson S.E., Chaudhuri M., Gish G., Pawson T., Haser W.G., et al. SH2 domains recognize specific phosphopeptide sequences. Cell 72 (1993) 767-778
117. Soriano P., Montgomery C., Geske R., and Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64 (1991) 693-702
118. Staber P.B., Linkesch W., Zauner D., Beham-Schmid C., Guelly C., Schauer S., et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 23 (2004) 894-904
119. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3 (2003) 650-665
120. de The H., Chomienne C., Lanotte M., Degos L., and Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347 (1990) 558-561
121. Takeya T., and Hanafusa H. Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus. Cell 32 (1983) 881-890
122. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
123. Tanaka T., Kurokawa M., Ueki K., Tanaka K., Imai Y., Mitani K., et al. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 16 (1996) 3967-3979
124. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13 (1997) 513-609
125. Tian S.S., Tapley P., Sincich C., Stein R.B., Rosen J., and Lamb P. Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood 88 (1996) 4435-4444
126. Towatari M., Iida H., Tanimoto M., Iwata H., Hamaguchi M., and Saito H. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 11 (1997) 479-484
127. Treinies I., Paterson H.F., Hooper S., Wilson R., and Marshall C.J. Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol 19 (1999) 321-329
128. Wang X., and Studzinski G.P. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J Cell Biochem 80 (2001) 471-482
129. Ward A.C., Monkhouse J.L., Csar X.F., Touw I.P., and Bello P.A. The Src-like tyrosine kinase Hck is activated by granulocyte colony-stimulating factor (G-CSF) and docks to the activated G-CSF receptor. Biochem Biophys Res Commun 251 (1998) 117-123
130. Williams J.C., Weijland A., Gonfloni S., Thompson A., Courtneidge S.A., Superti-Furga G., et al. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J Mol Biol 274 (1997) 757-775
131. Willman C.L., Stewart C.C., Griffith J.K., Stewart S.J., and Tomasi T.B. Differential expression and regulation of the c-src and c-fgr protooncogenes in myelomonocytic cells. Proc Natl Acad Sci U S A 84 (1987) 4480-4484
132. Willman C.L., Stewart C.C., Longacre T.L., Head D.R., Habbersett R., Ziegler S.F., et al. Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages. Blood 77 (1991) 726-734
133. Wilson M.B., Schreiner S.J., Choi H.J., Kamens J., and Smithgall T.E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 21 (2002) 8075-8088
134. Wu J., Wong W.W., Khosravi F., Minden M.D., and Penn L.Z. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64 (2004) 6461-6468
135. Xu W., Doshi A., Lei M., Eck M.J., and Harrison S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3 (1999) 629-638
136. Xu W., Harrison S.C., and Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385 (1997) 595-602
137. Yen A., Roberson M.S., Varvayanis S., and Lee A.T. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 58 (1998) 3163-3172
138. Yu C., Dai Y., Dent P., and Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. Cancer Biol Ther 1 (2002) 674-682
139. Yu C., Dasmahapatra G., Dent P., and Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 19 (2005) 1579-1589
140. Yu C., Krystal G., Varticovksi L., McKinstry R., Rahmani M., Dent P., et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62 (2002) 188-199
141. Yu C., Wang S., Dent P., and Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol 60 (2001) 143-154
142. Yu G., and Glazer R.I. Purification and characterization of p93fes- and p60src-related tyrosine protein kinase activities in differentiated HL-60 leukemia cells. J Biol Chem 262 (1987) 17543-17548
143. Yuan Y., Zhou L., Miyamoto T., Iwasaki H., Harakawa N., Hetherington C.J., et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 98 (2001) 10398-10403
144. Zhu Q.S., Xia L., Mills G.B., Lowell C.A., Touw I.P., and Corey S.J. G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood 107 (2006) 1847-1856